Cyrano Therapeutics CYR-064 Trial Data to Be Presented at American Rhinologic Society Meeting
Cyrano Therapeutics announced that results from its Phase 2 FLAVOR trial for CYR-064 will be presented at the American Rhinologic Society annual meeting. The trial evaluated CYR-064 for the treatment of persistent post-viral loss of smell.
Cyrano Therapeutics will present findings from its Phase 2 FLAVOR clinical trial evaluating the drug candidate CYR-064. The presentation will occur at the 72nd Annual Meeting of the American Rhinologic Society. The biotechnology company focuses on developing treatments for smell and taste disorders.
The Phase 2 trial data specifically examine the efficacy of CYR-064 in addressing persistent loss of smell following viral infections. This condition can significantly impact a patient's quality of life, highlighting the need for effective therapeutic options.
The presentation will be delivered orally, detailing the trial's outcomes. Cyrano Therapeutics aims to demonstrate CYR-064's potential as a treatment for individuals suffering from post-viral anosmia, a condition for which current treatment avenues are limited.
Cyrano Therapeutics is a clinical-stage regenerative medicine company. CYR-064 represents one of their key molecular candidates designed to restore olfactory function in patients who have experienced smell loss due to factors such as viral illness.